WTO declines to waive TRIPS provisions for COVID-19 drugs

Representatives of South Africa and India have again tried and failed to persuade the World Trade Organization (WTO) to waive IP rights related to COVID-19 treatments and vaccinations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

WTO releases draft COVID-19 response after ‘very difficult process’

14 June 2022 The World Trade Organization has issued draft texts relating to its IP response to the COVID-19.

Biotechnology

WTO fails to strike deal to waive COVID-19 IP

20 October 2020 Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation to conclude an agreement.

Big Pharma

South Africa, India urge WTO to waive IP for COVID-19 treatments

8 October 2020 South Africa and India have asked the World Trade Organization to cede some stipulations governing IP so that treatments to combat COVID-19 can become more widely available, particularly in low-income countries.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

WTO declines to waive TRIPS provisions for COVID-19 drugs

More on this story

Editor's picks

Editor's picks

More features